Stocktoria
Sanara MedTech Inc. SMTI
Sanara MedTech Inc. (SMTI) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $103.1M at a -36.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.204 |
| Retained earnings / assets | -1.032 |
| EBIT / assets | 0.1 |
| Equity / liabilities | 0.089 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SMTI | Sanara MedTech Inc. | 4/9 | -1.26 | — | +19% |
| APT | ALPHA PRO TECH LTD | 4/9 | 12.4 | 16.1 | +2.3% |
| MYO | MYOMO, INC. | 3/9 | -8.82 | — | +25.7% |
| LFWD | Lifeward Ltd. | 4/9 | — | — | -14.1% |
| ZJYL | Jin Medical International Ltd. | 4/9 | 5.16 | 15.7 | -12% |
| LAKE | LAKELAND INDUSTRIES INC | 2/9 | 4.56 | — | +15.2% |
| MLSS | MILESTONE SCIENTIFIC INC. | 2/9 | — | — | — |
About Sanara MedTech Inc.
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
FAQ
Is SMTI financially healthy?
Sanara MedTech Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SMTI pay a dividend?
No, Sanara MedTech Inc. does not currently pay a dividend.
How profitable is SMTI?
In FY2025, Sanara MedTech Inc. had a net margin of -36.4% and a return on equity of -632.5%.
What is the analyst price target for SMTI?
The average Wall-Street price target for Sanara MedTech Inc. is $34.33, about 0.0% above the recent price, from 3 analysts (consensus: strong buy).
Is SMTI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Sanara MedTech Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.